西部中医药
西部中醫藥
서부중의약
GANSU JOURNAL OF TRADITIONAL CHINESE MEDICINE
2013年
8期
92-93
,共2页
食管癌术后%中药%辅助治疗
食管癌術後%中藥%輔助治療
식관암술후%중약%보조치료
after the surgery of esophageal cancer%TCM%adjuvant treatment
目的：观察食管癌术后使用中药辅助治疗的临床疗效；方法：将72例食管癌术后患者分为观察组42例、对照组30例，2组患者术后均接受化疗，观察组在此基础上予中药内服，2组共治疗2个疗程。治疗期间每周进行一次卡氏评分以评价其生活质量改善情况，并在治疗前后检测静脉血中T淋巴细胞亚群和免疫球蛋白含量变化情况，以评估患者免疫功能情况。结果：卡氏评分结果显示观察组病情改善31例，稳定11例，未见恶化病例，对照组病情改善17例，稳定12例，恶化1例；经卡方检验χ2=11.1669，P=0.0109。2组T淋巴细胞亚群CD3+、CD4+、CD8+变化经t检验可得t=2.3.32，P=0.0242；2组免疫球蛋白IgA、IgG、IgM变化经t检验可得t=2.5614，P=0.0126，2组比较差异具有统计学意义。结论：中药汤剂能提高食管癌术后患者生活质量与免疫功能，可作为辅助治疗在临床上推广使用。
目的：觀察食管癌術後使用中藥輔助治療的臨床療效；方法：將72例食管癌術後患者分為觀察組42例、對照組30例，2組患者術後均接受化療，觀察組在此基礎上予中藥內服，2組共治療2箇療程。治療期間每週進行一次卡氏評分以評價其生活質量改善情況，併在治療前後檢測靜脈血中T淋巴細胞亞群和免疫毬蛋白含量變化情況，以評估患者免疫功能情況。結果：卡氏評分結果顯示觀察組病情改善31例，穩定11例，未見噁化病例，對照組病情改善17例，穩定12例，噁化1例；經卡方檢驗χ2=11.1669，P=0.0109。2組T淋巴細胞亞群CD3+、CD4+、CD8+變化經t檢驗可得t=2.3.32，P=0.0242；2組免疫毬蛋白IgA、IgG、IgM變化經t檢驗可得t=2.5614，P=0.0126，2組比較差異具有統計學意義。結論：中藥湯劑能提高食管癌術後患者生活質量與免疫功能，可作為輔助治療在臨床上推廣使用。
목적：관찰식관암술후사용중약보조치료적림상료효；방법：장72례식관암술후환자분위관찰조42례、대조조30례，2조환자술후균접수화료，관찰조재차기출상여중약내복，2조공치료2개료정。치료기간매주진행일차잡씨평분이평개기생활질량개선정황，병재치료전후검측정맥혈중T림파세포아군화면역구단백함량변화정황，이평고환자면역공능정황。결과：잡씨평분결과현시관찰조병정개선31례，은정11례，미견악화병례，대조조병정개선17례，은정12례，악화1례；경잡방검험χ2=11.1669，P=0.0109。2조T림파세포아군CD3+、CD4+、CD8+변화경t검험가득t=2.3.32，P=0.0242；2조면역구단백IgA、IgG、IgM변화경t검험가득t=2.5614，P=0.0126，2조비교차이구유통계학의의。결론：중약탕제능제고식관암술후환자생활질량여면역공능，가작위보조치료재림상상추엄사용。
Objective:To observe curative effects of postoperative adjuvant treatment for the patients after the surgery of esophageal cancer with TCM. Method:Seventy-two patients were divided into 42 cases of the observation group and 30 cases of the control group, both groups received chemotherapy, the observation group took herbs, both groups were treated for two courses of treatment. The improvements of life quality were evaluated during the treat-ment by Karnofsky's performance scale each week, the changes of immunoglobulin and T-lymphocyte subsets con-tents were detected before and after treating in the venous blood to assess immunologic function of the patients. Re-sult:Karnofsky results revealed that there were 31 cases improved, 11 cases stable and no case deteriorated in the observation group, 17 cases improved, 12 cases stable and one case deteriorated in the control group;detected with chi-square test χ2=11.1669, P=0.0109. The changes of T-lymphocyte subsets including CD3+, CD4+ and CD8+showed that t=2.332, P=0.0242 by T test;the changes of immunoglobulin including IgA, IgG and IgM were detected with T test and the results showed t=2.5614, P=0.0126, the difference had statistical meaning. Conclusion:TCM de-coction could improve life quality and immunologic function of the patients after the surgery of esophageal cancer, which could be spread as adjuvant treatment.
